All In Biotech

Drug Trial Radar · NCT07065617

A Study to Test How BI 1819479 is Taken up and Processed by the Body

A Phase I, Open-label, Two-part Trial to Investigate the Mass Balance, Metabolism, and Basic Pharmacokinetics of BI 1819479 (C-14) Administered as an Oral Solution (Part A) and to Investigate the Absolute Bioavailability of BI 1819479 Administered as a Film-coated Tablet Together With an Intravenous Microtracer Dose of [14 C]BI 1819479 (Part B) in Healthy Male Volunteers

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

7

Actual

Start

Aug 4, 2025

Primary completion

Oct 4, 2025

Study completion Nov 4, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jul 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial is intended to investigate the mass balance, metabolism, and basic pharmacokinetics of BI 1819479 (C-14) (Part A) and to investigate the absolute bioavailability of BI 1819479 (Part B) in healthy male volunteers.

Conditions

  • Healthy

Interventions

  • [14C]BI 1819479Drug

    \[14C\]BI 1819479

  • BI 1819479Drug

    BI 1819479

  • BI 1819479 (C-14)Drug

    BI 1819479 mixed with \[14C\]BI 1819479

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: fraction of [14C]-radioactivity excreted in urine as percentage of the administered dose over the time interval from 0 to the last quantifiable time point (fe urine, 0-tz)Time frame: Up to 37 days.
  2. Part A: fraction of [14C]-radioactivity excreted in urine as percentage of the administered dose over the time interval from 0 to the last quantifiable time point (fe faeces, 0-tz)Time frame: Up to 37 days.
  3. Part B: area under the concentration-time curve of [14C]BI 1819479 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)Time frame: Up to 31 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.